title: Insulin pump therapy management in very young children with type 1 diabetes using continuous subcutaneous insulin infusion.
abstract: BACKGROUND
  Compared to older children and adolescents very young patients with type 1 diabetes represent a unique population. We analyzed the age-dependent characteristics and parameters of continuous subcutaneous insulin infusion (CSII) in children under 6 years of age with type 1 diabetes.
  
  
  METHODS
  We evaluated metabolic control and pump-dependent characteristics in 46 children with type 1 diabetes after 0.89 +/- 0.62 years of CSII.
  
  
  RESULTS
  Metabolic control significantly improved after CSII initiation (glycosylated hemoglobin, 8.12 +/- 1.24% vs. 7.30 +/- 0.67%; P < 0.05), without increased risk for diabetic ketoacidosis or hypoglycemia. Interestingly, very young patients required bigger boluses than expected, especially in the morning and at the afternoon snack.
  
  
  CONCLUSIONS
  These data support the need to personalize pump-dependent characteristics, especially in very young children with type 1 diabetes, in order to optimize CSII therapy in this unique age group of patients.
authors.affiliation: Department of Paediatrics, University of Turin, Italy. ivana.rabbone@unito.it
authors.forename: Ivana
authors.initials: I
authors.lastname: Rabbone
authors.forename: Andrea
authors.initials: A
authors.lastname: Scaramuzza
authors.forename: Adriana
authors.initials: A
authors.lastname: Bobbio
authors.forename: Riccardo
authors.initials: R
authors.lastname: Bonfanti
authors.forename: Dario
authors.initials: D
authors.lastname: Iafusco
authors.forename: Fortunato
authors.initials: F
authors.lastname: Lombardo
authors.forename: Sonia
authors.initials: S
authors.lastname: Toni
authors.forename: Stefano
authors.initials: S
authors.lastname: Tumini
authors.forename: Franco
authors.initials: F
authors.lastname: Cerutti
mesh_terms: D000367:Age Factors; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D007332:Insulin Infusion Systems / Q000009:adverse effects*; D008137:Longitudinal Studies; D008297:Male
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin